Compare SSBI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | ATYR |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | 106 | 58 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.7M | 73.7M |
| IPO Year | N/A | N/A |
| Metric | SSBI | ATYR |
|---|---|---|
| Price | $13.67 | $0.84 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 4.1K | ★ 948.2K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $0.64 |
| 52 Week High | $14.00 | $7.29 |
| Indicator | SSBI | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 49.72 |
| Support Level | $12.78 | $0.82 |
| Resistance Level | $13.68 | $0.86 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 87.51 | 65.60 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).